Q15788 (NCOA1_HUMAN) Homo sapiens (Human)
Nuclear receptor coactivator 1 UniProtKBInterProSTRINGInteractive Modelling
It is possible new templates exist for this target since these models were created.
Available Structures
285 Experimental Structures
| Description | PDB ID | Oligo-state | Range | Seq id (%) | Ligands | |
|---|---|---|---|---|---|---|
| Insight into the molecular recognition mechanism of the coactivator NCoA1 by STAT6 |
Heteromer P42226; | 99.22 | ||||
| LIGAND-BINDING DOMAIN OF THE HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA |
Heteromer P37231; | 100.0 | 1×BRL; | |||
| Structural diversity in CBP p160 complexes |
Heteromer P45481; | 94.55 | ||||
| Crystal Structure of the SR12813-bound PXR/RXRalpha LBD Heterotetramer Complex |
Heteromer O75469; P19793; | 100.0 | 2×SRL; | |||
| PPARgamma-RXRalpha(S427F) heterodimer in complex with SRC-1, rosiglitazone, and 9-cis-retanoic acid |
Heteromer P19793; P37231; | 100 | 1×9CR; 1×BRL; | |||
| Crystal Structure of PPAR Gamma with N-sulfonyl-2-indole carboxamide ligands |
Heteromer P37231; | 100 | 2×NSI; | |||
| Structure of pregnane X receptor in complex with a Sphingosine 1- Phosphate Receptor 1 Antagonist |
Heteromer O75469; | 100 | 2×D7E; | |||
| Structure of PPARgamma with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid |
Heteromer P37231; | 100 | 1×ET1; | |||
| THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMM… |
Heteromer P19793; P37231; | 100 | 1×9CR; 1×BRL; | |||
| THE 2.1 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF THE HUMAN RXRALPHA AND PPARGAMM… |
Heteromer P19793; P37231; | 100 | 1×9CR; 1×570; | |||
| Crystal structure of pregnane X receptor ligand binding domain complexed with JQ1 |
Heteromer O75469; | 100 | 2×JQ1; | |||
| The 2.3 Angstrom resolution crystal structure of the heterodimer of the human PPARgamma and RXRalph… |
Heteromer P19793; P37231; | 100 | 1×9CR; 1×544; | |||
| Molecular recognition of nitro-fatty acids by PPAR gamma |
Heteromer P37231; | 100 | 1×LNA; 1×LNB; | |||
| Crystal structure of PPARgamma in complex with compound 13 |
Heteromer P37231; | 100 | 1×14R; | |||
| X-Ray Crystal Structure of LXR Ligand Binding Domain with 24(S),25-epoxycholesterol |
Heteromer P55055; | 100 | 1×CO1; | |||
| Identification of LXRbeta selective agonists for the treatment of Alzheimer's Disease |
Heteromer Q13133; | 100 | 2×668; 2×SO4; | |||
| X-ray structure of GW3965 synthetic agonist bound to the LXR-alpha |
Heteromer Q13133; | 100 | 2×965; 2×SO4; | |||
| Crystal Structure of the human PXR-LBD in complex with an SRC-1 coactivator peptide and SR12813 |
Heteromer O75469; | 100 | 1×SRL; | |||
| X-ray structure of benzisoxazole synthetic agonist bound to the LXR-alpha |
Heteromer Q13133; | 100 | 2×SO4; 2×O90; | |||
| the crystal structure of the human PPARaplpha ligand binding domain in complex with a a-hydroxyimin… |
Heteromer Q07869; | 100 | 1×MMB; | |||
| X-ray structure of benzisoxazole urea synthetic agonist bound to the LXR-alpha |
Heteromer Q13133; | 100 | 2×O40; 2×SO4; | |||
| Structure of PPARalpha with 3-[5-Methoxy-1-(4-methoxy-benzenesulfonyl)-1H-indol-3-yl]-propionic acid |
Heteromer Q07869; | 100 | 1×ET1; | |||
| Crystal Structure of PXR LBD Complexed with SJB7 |
Heteromer O75469; | 100 | 2×4WH; | |||
| Crystal structure of LXRalpha in complex with tert-butyl benzoate analog, compound 4 |
Heteromer Q13133; | 100 | 2×4KM; | |||
| Crystal structure of LXRalpha in complex with tert-butyl benzoate analog, compound 32b |
Heteromer Q13133; | 100 | 2×4KQ; | |||
| Crystal structure of human FXR/RXR-LBD heterodimer bound to HNC180 and 9cRA and SRC1 |
Heteromer P19793; Q96RI1; | 100 | 1×9R3; 1×9CR; | |||
| X-ray structure of human PPARalpha ligand binding domain-clofibric acid-SRC1 coactivator peptide co… |
Heteromer Q07869; | 100 | 2×E0O; | |||
| Crystal structure of HNF4a LBD in complex with the ligand and the coactivator SRC-1 peptide |
Heteromer P41235; | 100 | 1×MYR; | |||
| Crystal structure of PPARgamma with compound BR101549 |
Heteromer P37231; | 100 | 1×AE0; | |||
| X-ray structure of human PPARalpha ligand binding domain-fenofibric acid-SRC1 coactivator peptide c… |
Heteromer Q07869; | 100 | 2×F5A; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | ||||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9LS; | |||
| Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi… |
Heteromer Q96RI1; | 100 | 1×OMM; | |||
| Crystal structure of human FXR/RXR-LBD heterodimer bound to HNC143 and 9cRA and SRC1 |
Heteromer P19793; Q96RI1; | 100 | 1×9R0; 2×SO4; 1×9CR; 1×PO4; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×643; | |||
| Identification of an N-oxide pyridine GW4064 analogue as a potent FXR agonist |
Heteromer Q96RI1; | 100 | 1×643; | |||
| X-ray structure of human PPAR gamma ligand binding domain-seladelpar-SRC1 coactivator peptide co-cr… |
Heteromer P37231; | 100 | 1×KKB; | |||
| The 2.5 Angstrom resolution crystal structure of the human PPARalpha ligand binding domain bound wi… |
Heteromer Q07869; | 100 | 1×544; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9LA; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9MM; | |||
| Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzimida… |
Heteromer Q96RI1; | 100 | 1×OMK; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9MY; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×CL; 1×9L7; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9LP; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9LV; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9LG; | |||
| Structural and Biochemical Mechanisms for the Specificity of Hormone Binding and Coactivator Assemb… |
Heteromer P08235; | 100 | 1×C0R; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9O1; | |||
| Crystal structure of human FXR in complex with (2S)-2-[2-(4-chlorophenyl)-1H-benzimidazol-1-yl]-N,2… |
Heteromer Q96RI1; | 100 | 1×OKI; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9N4; | |||
| Crystal Structure of Peroxisome Proliferator-Activated Receptor Gamma (PPARg) and Retinoic Acid Rec… |
Heteromer P19793; P37231; | 100 | 1×9RA; 1×D30; | |||
| Crystal structure of estrogen receptor beta complexed with 3-Bromo-6-hydroxy-2-(4-hydroxy-phenyl)-i… |
Heteromer Q92731; | 91.67 | 2×789; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9M7; | |||
| Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi… |
Heteromer Q96RI1; | 100 | 1×OOK; | |||
| Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi… |
Heteromer Q96RI1; | 100 | 1×OOF; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9N7; | |||
| Crystal Structure of PPARg in complex with INT131 |
Heteromer P37231; | 100 | 1×Z12; 1×CL; | |||
| X-ray structure of human PPAR gamma ligand binding domain-bezafibrate co-rystals obtained by co-cry… |
Heteromer P37231; | 100 | 1×PEM; | |||
| MR in complex with desisobutyrylciclesonide |
Heteromer P08235; | 100 | 1×DMS; 1×GOL; 1×SO4; 1×CV7; | |||
| Crystal structure of LXR ligand binding domain in complex with full agonist 1 |
Heteromer P55055; | 100 | 2×0KS; 1×ACT; 7×CA; | |||
| Revealing a steroid receptor ligand as a unique PPARgamma agonist |
Heteromer P37231; | 100 | 1×486; | |||
| Crystal structure of the agonist-bound ligand-binding domain of Biomphalaria glabrata RXR |
Heteromer Q8T5C6; | 100 | 4×9CR; | |||
| Crystal structure of FXR in complex with agonist XJ034 |
Heteromer Q96RI1; | 100 | 1×AWL; | |||
| crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid and CITCO |
Heteromer P19793; Q14994; | 100 | 1×F15; | |||
| crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid, and 5b-pregnane-3,20-… |
Heteromer P19793; Q14994; | 100 | 1×F15; | |||
| Crystal structure of LXR ligand binding domain in complex with partial agonist 5 |
Heteromer P55055; | 100 | 2×0KT; 1×ACT; 6×CA; | |||
| FXR-LBD with HNC143 and SRC1 |
Heteromer Q96RI1; | 100 | 1×9R0; | |||
| Human Estrogen Receptor beta Ligand-binding Domain in Complex with S-DPN |
Heteromer Q92731; | 100 | 2×I0K; | |||
| Crystal structure of hERa-LBD (Y537S) in complex with estradiol |
Heteromer P03372; | 100 | 2×EST; 3×GOL; 1×EDO; | |||
| a crystal structure of PPAR alpha bound with SRC1 peptide and GW735 |
Heteromer Q07869; | 100 | 1×735; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9NG; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9ND; | |||
| Human Estrogen Receptor beta Ligand-binding Domain in Complex with (R)-2-(2-chloro-4-hydroxyphenyl)… |
Heteromer Q92731; | 100 | 2×I1M; | |||
| Crystal structure of human FXR in complex with 4-({(2S)-2-[2-(4-chlorophenyl)-5,6-difluoro-1H-benzi… |
Heteromer Q96RI1; | 100 | 1×OLF; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9MP; | |||
| Crystal structure of RARb LBD homodimer in complex with TTNPB |
Heteromer P10826; | 100 | 1×TTB; | |||
| Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator |
Heteromer P37231; | 100 | 1×CEK; | |||
| Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator |
Heteromer P37231; | 100 | 1×FCM; | |||
| Structure of human FXR in complex with MFA-1 and co-activator peptide |
Heteromer Q96RI1; | 100 | 1×YT3; 1×MUF; | |||
| Human Estrogen Receptor beta Ligand-binding Domain in Complex with (S)-3-(2-chloro-4-hydroxyphenyl)… |
Heteromer Q92731; | 100 | 2×I1I; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9N1; | |||
| X-ray structure of human PPARalpha ligand binding domain-GW7647-SRC1 coactivator peptide co-crystal… |
Heteromer Q07869; | 100 | 1×2VN; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9MA; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9KV; | |||
| Human PPARgamma ligand binding domain complexed with Rosiglitazone |
Heteromer P37231; | 100 | 1×BRL; | |||
| Human Estrogen Receptor beta Ligand-binding Domain in Complex with (R)-3-(2-chloro-4-hydroxyphenyl)… |
Heteromer Q92731; | 100 | 2×I1D; | |||
| Crystal structure of the PPARgamma-LBD complexed with a cercosporamide derivative modulator |
Heteromer P37231; | 100 | 1×24L; | |||
| Human PPARgamma ligand binding dmain complexed with S35 |
Heteromer P37231; | 100 | 1×T35; 1×MYR; 1×GOL; | |||
| VDR complex |
Heteromer Q9PTN2; | 100 | 2×AYK; | |||
| Allene-Based Design of a Noncalcemic Vitamin D Receptor Agonist |
Heteromer Q9PTN2; | 100 | 2×T0H; 2×ACT; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9LM; | |||
| Human PPARgamma ligand binding domain complexed with SB1494 |
Heteromer P37231; | 100 | 1×A9F; | |||
| Human PPARgamma ligand binding domain complexed with Lobeglitazone |
Heteromer P37231; | 100 | 1×8LX; | |||
| CRYSTAL STRUCTURE OF FARNESOID X-ACTIVATED RECEPTOR COMPLEXED WITH COMPOUND-32 AKA (1S,3S)-N-({4-[5… |
Heteromer Q96RI1; | 100 | 1×IUS; | |||
| Vitamin D receptor complex |
Heteromer Q9PTN2; | 100 | 2×B0B; | |||
| Human Estrogen Receptor beta Ligand-binding Domain in Complex with (S)-2-(2-chloro-4-hydroxyphenyl)… |
Heteromer Q92731; | 100 | 2×I2B; | |||
| Crystal Structure of PPARgamma complexed with Telmisartan |
Heteromer P37231; | 100 | 1×TLS; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9NP; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9LY; | |||
| The ligand-free structure of human PPARgamma LBD R288H mutant in the presence of the SRC-1 coactiva… |
Heteromer P37231; | 100 | 1×MLI; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9M1; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9NJ; | |||
| Crystal structure of RARbeta LBD in complex with LG 100754 |
Heteromer P10826; | 100 | 2×754; 1×FLC; 1×GOL; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9NA; | |||
| The ligand-free structure of human PPARgamma LBD Q286E mutant in the presence of the SRC-1 coactiva… |
Heteromer P37231; | 100 | ||||
| FXR bound to a quinolinecarboxylic acid |
Heteromer Q96RI1; | 100 | 1×89P; 1×SO4; | |||
| Human PPARgamma ligand binding dmain complexed with SB1453 in a covalent bonded form |
Heteromer P37231; | 100 | 1×T53; | |||
| The ligand-free structure of human PPARgamma LBD F287Y mutant in the presence of the SRC-1 coactiva… |
Heteromer P37231; | 100 | 1×MLI; | |||
| Crystal structure of RARbeta LBD in complex with agonist BMS411 [4-{[(5,5-dimethyl-8-phenyl-5,6-dih… |
Heteromer P10826; | 100 | 2×1NY; 1×PE4; 1×FLC; | |||
| The ligand-free structure of human PPARgamma LBD C285Y mutant in the presence of the SRC-1 coactiva… |
Heteromer P37231; | 100 | 1×MLA; | |||
| The agonist-free structure of human PPARgamma ligand binding domain in the presence of the SRC-1 co… |
Heteromer P37231; | 100 | 1×MYR; 1×GOL; | |||
| A novel moderator XD4 for bile acid receptor |
Heteromer Q96RI1; | 90.91 | 1×XD4; 1×SO4; | |||
| CRYSTAL STRUCTURE OF THE LIGAND-BINDING DOMAIN OF THE ESTROGEN-RELATED RECEPTOR GAMMA IN COMPLEX WI… |
Heteromer P62508; | 100 | ||||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9L4; | |||
| X-ray structure of human PPARalpha ligand binding domain-bezafibrate-SRC1 coactivator peptide co-cr… |
Heteromer Q07869; | 100 | 1×PEM; | |||
| Crystal structure of PPARgamma with compound BR102375K |
Heteromer P37231; | 100 | 2×GOL; 1×A0L; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9LJ; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9KY; | |||
| FXR with SRC1 and GW4064 |
Heteromer Q96RI1; | 100 | 1×064; | |||
| Doubling the Size of the Glucocorticoid Receptor Ligand Binding Pocket by Deacylcortivazol |
Heteromer P04150; | 100 | 1×DAY; | |||
| Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain |
Heteromer Q9PTN2; | 100 | 2×9CZ; | |||
| FXR with SRC1 and GSK237 |
Heteromer Q96RI1; | 100 | 2×SO4; 1×37G; | |||
| X-ray structure of human PPAR gamma ligand binding domain-fenofibric acid co-crystals obtained by c… |
Heteromer P37231; | 100 | 3×F5A; | |||
| The ligand-free structure of human PPARgamma LBD in the presence of the SRC-1 coactivator peptide |
Heteromer P37231; | 100 | ||||
| crystal structure of the RARalpha/RXRalpha ligand binding domain heterodimer in complex with a frag… |
Heteromer P10276; P28700; | 100 | 1×LG2; 1×GOL; 1×EQN; | |||
| FXR-LBD with HNC180 and SRC1 |
Heteromer Q96RI1; | 100 | 5×SO4; 1×9R3; | |||
| FXR with SRC1 and GSK826 |
Heteromer Q96RI1; | 100 | 1×82X; 2×SO4; | |||
| Crystal structure of RARbeta LBD in complex with selective agonist BMS948 [4-{[(8-phenylnaphthalen-… |
Heteromer P10826; | 100 | 2×JYH; 1×FLC; | |||
| The ligand-free structure of human PPARgamma LBD R288C mutant in the presence of the SRC-1 coactiva… |
Heteromer P37231; | 100 | ||||
| X-ray structure of the orphan nuclear receptor ERR3 ligand-binding domain in the constitutively act… |
Heteromer P62508; | 100 | ||||
| The ligand-free structure of human PPARgamma LBD S289C mutant in the presence of the SRC-1 coactiva… |
Heteromer P37231; | 100 | 1×MLA; | |||
| Side-chain fluorine atoms of non-steroidal vitamin D3 analogs stabilize helix 12 of vitamin D recep… |
Heteromer Q9PTN2; | 100 | 2×MG; 2×C5D; | |||
| Human PPARgamma ligand-binding domain R288A mutant in complex with imatinib |
Heteromer P37231; | 100 | 1×STI; | |||
| Identification of a unique PPAR ligand with an unexpected binding mode and antibetic activity |
Heteromer P37231; | 100 | 1×0W3; | |||
| Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear R… |
Heteromer Q9PTN2; | 100 | 2×0VP; | |||
| Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear R… |
Heteromer Q9PTN2; | 100 | 2×0VK; | |||
| FXR with SRC1 and GSK8062 |
Heteromer Q96RI1; | 100 | 1×O62; | |||
| FXR bound to isoquinolinecarboxylic acid |
Heteromer Q96RI1; | 100 | 1×P88; 1×SO4; | |||
| FXR with SRC1 and GSK359 |
Heteromer Q96RI1; | 100 | 2×SO4; 1×59G; | |||
| Crystal structure of human FXR/RXR-LBD heterodimer bound to GW4064 and 9cRA and SRC1 |
Heteromer P19793; Q96RI1; | 100 | 1×064; 1×9CR; | |||
| FXR with SRC1 and GSK2034 |
Heteromer Q96RI1; | 100 | 1×SO4; 1×034; | |||
| FXR with SRC1 and GSK088 |
Heteromer Q96RI1; | 100 | 1×088; 1×SO4; | |||
| Ternary complex of hPPARalpha ligand binding domain, 17-oxoDHA and a SRC1 peptide |
Heteromer Q07869; | 100 | 1×4M5; | |||
| Characterization of ligands for the orphan nuclear receptor RORbeta |
Heteromer P45446; | 100 | 1×ARL; | |||
| Crystal structure of phosphorylated estrogen receptor beta ligand binding domain |
Heteromer Q92731; | 100 | 1×EST; | |||
| X-ray structure of human PPARalpha ligand binding domain-pemafibrate-SRC1 coactivator peptide co-cr… |
Heteromer Q07869; | 100 | 1×P7F; 1×GOL; | |||
| X-ray structure of human PPARalpha ligand binding domain-intrinsic fatty acid (E. coli origin)-SRC1… |
Heteromer Q07869; | 100 | 1×PLM; 1×GOL; | |||
| Mineralocorticoid receptor in complex with (s)-13 |
Heteromer P08235; | 100 | 3×GOL; 1×EWN; | |||
| X-ray structure of human PPARalpha ligand binding domain-eicosapentaenoic acid (EPA)-SRC1 coactivat… |
Heteromer Q07869; | 100 | 1×EPA; 1×GOL; | |||
| The structure of MR in complex with eplerenone. |
Heteromer P08235; | 100 | 1×YNU; | |||
| Crystal structure of RARalpha ligand binding domain in complex with an agonist ligand (Am580) and a… |
Heteromer P10276; | 100 | 1×EQN; | |||
| Crystal structure of hERa-LBD (Y537S) in complex with 4-tert-octylphenol |
Heteromer P03372; | 100 | 2×27L; | |||
| Mineralocorticoid receptor in complex with (s)-13 |
Heteromer P08235; | 100 | 1×MPD; 1×EY8; | |||
| The structure of MR in complex with AZD9977. |
Heteromer P08235; | 100 | 1×ECV; | |||
| MCR IN COMPLEX WITH ligand |
Heteromer P08235; | 100 | 1×6QG; 1×NHE; | |||
| Crystal structure of hERa-LBD (Y537S) in complex with TCBPA |
Heteromer P03372; | 100 | 2×XDH; 2×GOL; | |||
| Human PPARgamma ligand binding dmain complexed with R35 |
Heteromer P37231; | 100 | 1×Q35; | |||
| Crystal structure of hERa-LBD (Y537S) in complex with alpha-zearalanol |
Heteromer P03372; | 100 | 2×27J; 1×GOL; 3×EDO; | |||
| MCR IN COMPLEX WITH ligand |
Heteromer P08235; | 100 | 1×NHE; 1×MPD; 1×SO4; 2×EDO; 1×6Q0; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9MD; | |||
| Crystal structure of RARbeta LBD in complex with selective partial agonist BMS641 [3-chloro-4-[(E)-… |
Heteromer P10826; | 100 | 2×JYI; 1×FLC; | |||
| X-ray structure of the orphan nuclear receptor ROR beta ligand-binding domain in the active conform… |
Heteromer P45446; | 100 | 1×STE; | |||
| Crystal structure of hERa-LBD (Y537S) in complex with HPTE |
Heteromer P03372; | 100 | 2×27N; 1×GOL; 1×EDO; | |||
| Fragment-Based Design of novel Estrogen Receptor Ligands |
Heteromer Q92731; | 100 | 1×W23; | |||
| Identification of a novel PPARg ligand that regulates metabolism |
Heteromer P37231; | 100 | 1×CTI; | |||
| 1a,20S-dihydroxyvitamin D3 VDR complex |
Heteromer Q9PTN2; | 100 | 2×D3V; | |||
| A novel anti-adipogenic partial agonist of peroxisome proliferator-activated receptor-gamma (PPARG)… |
Heteromer P37231; | 100 | 1×RO0; 1×GOL; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9MS; | |||
| VDR complex of a side-chain hydroxylated derivatives of lithocholic acid |
Heteromer Q9PTN2; | 100 | 2×2WV; | |||
| MCR IN COMPLEX WITH ligand |
Heteromer P08235; | 100 | 1×EDO; 1×6QE; | |||
| Design and biological evaluation of novel, balanced dual PPARa/g agonists |
Heteromer P37231; | 100 | 1×CTM; | |||
| MR in complex with dexamethasone |
Heteromer P08235; | 100 | 1×GOL; 1×DEX; | |||
| Crystal structure of hERa-LBD (Y537S) in complex with chlordecone |
Heteromer P03372; | 100 | 3×GOL; 2×A1AQV; | |||
| Fragment-Based Design of novel Estrogen Receptor Ligands |
Heteromer Q92731; | 100 | 1×W14; | |||
| Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain |
Heteromer Q9PTN2; | 100 | 2×91W; | |||
| Characterization of ligands for the orphan nuclear receptor RORbeta |
Heteromer P45446; | 100 | 1×REA; | |||
| Crystal Structure of Estrogen Receptor Beta Complexed with WAY-555 |
Heteromer Q92731; | 100 | 2×555; | |||
| Crystal structure of hERa-LBD (Y537S) in complex with biochanin A |
Heteromer P03372; | 100 | 2×QSO; 2×GOL; 1×EDO; | |||
| VDR LBD complex with 25-nitro derivative of 1,25D3 |
Heteromer Q9PTN2; | 100 | 1×ACT; 1×UYO; | |||
| Structure-based Design of Indole Propionic Acids as Novel PPARag CO-Agonists |
Heteromer P37231; | 100 | 1×208; | |||
| Vitamin D receptor complex with 25-amine derivative of 1,25D3 |
Heteromer Q9PTN2; | 100 | 2×ACT; 2×UYU; | |||
| Crystal structure of hERa-LBD (Y537S) in complex with ferutinine |
Heteromer P03372; | 100 | 2×27H; 2×EDO; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9M4; | |||
| Crystal structure of estrogen receptor beta ligand binding domain |
Heteromer Q92731; | 100 | 1×EST; | |||
| Crystal structure of the LBD of VDR of Danio rerio in complex with calcitriol |
Heteromer Q9PTN2; | 100 | 2×VDX; | |||
| Human PPARgamma ligand binding dmain in complex with SR1664 |
Heteromer P37231; | 100 | 1×3JX; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9L1; | |||
| VDR complex with a side-chain hydroxylated derivative of lithocholic acid |
Heteromer Q9PTN2; | 100 | 2×2UI; | |||
| Fragment-Based Design of novel Estrogen Receptor Ligands |
Heteromer Q92731; | 100 | 1×WV7; | |||
| X-ray structure of human PPAR gamma ligand binding domain-lanifibranor-SRC1 coactivator peptide co-… |
Heteromer P37231; | 100 | 1×BJB; | |||
| RXRa structure complexed with CU-6PMN and SRC1 peptide. |
Heteromer P19793; | 100 | 2×WY5; | |||
| Aleglitaar. a new. potent, and balanced dual ppara/g agonist for the treatment of type II diabetes |
Heteromer P37231; | 100 | 1×RO7; | |||
| Crystal structure of zVDR L337H mutant-VD complex |
Heteromer Q9PTN2; | 100 | 2×VDX; | |||
| Nuclear receptor DAF-12 from parasitic nematode Strongyloides stercoralis in complex with its physi… |
Heteromer Q9XZJ5; | 100 | 1×DL7; | |||
| Nuclear receptor DAF-12 from parasitic nematode Strongyloides stercoralis in complex with its physi… |
Heteromer Q9XZJ5; | 100 | 1×DL4; | |||
| Potent Vitamin D Receptor Agonist |
Heteromer Q9PTN2; | 100 | 2×M7E; | |||
| Vitamin D receptor complex |
Heteromer Q9PTN2; | 100 | 2×AYT; | |||
| X-ray structure of human PPAR gamma ligand binding domain-pemafibrate co-crystals obtained by co-cr… |
Heteromer P37231; | 100 | 1×P7F; | |||
| Crystal structure of human FXR in complex with 2-(4-chlorophenyl)-1-[(1S)-1-cyclohexyl-2-(cyclohexy… |
Heteromer Q96RI1; | 100 | 2×OKH; | |||
| Structure of lamprey VDR in complex with 1,25D3 |
Heteromer S4R4S2; | 100 | 1×VDX; 2×MG; | |||
| Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear R… |
Heteromer Q9PTN2; | 100 | 2×0VQ; | |||
| Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear R… |
Heteromer Q9PTN2; | 100 | 2×0VP; | |||
| Vitamin D nuclear receptor complex 1 |
Heteromer Q9PTN2; | 100 | 2×E05; | |||
| Ligand binding domain of PPARgamma complexed with a benzimidazole partial agonist |
Heteromer P37231; | 100 | 1×M0T; | |||
| VDR complex with gemini analog UG-480 |
Heteromer Q9PTN2; | 100 | 2×A1H75; | |||
| Crystal structure of the ligand binding domain of the Vitamin D nuclear receptor in complex with Ge… |
Heteromer Q9PTN2; | 100 | 2×BIV; | |||
| VDR complex with Aromatic-D-Ring Analog |
Heteromer Q9PTN2; | 100 | 1×ACT; 1×IV1; | |||
| VDR complex with aromatic D-ring analog |
Heteromer Q9PTN2; | 100 | 1×ACT; 1×IV5; | |||
| Crystal structure of Vitamin D nuclear receptor ligand binding domain bound to a locked side-chain … |
Heteromer Q9PTN2; | 100 | 2×XE4; | |||
| VDR complex with BXL-62 |
Heteromer Q9PTN2; | 100 | 1×U5W; | |||
| The ligand-free structure of human PPARgamma ligand-binding domain R288A mutant in the presence of … |
Heteromer P37231; | 100 | ||||
| Revealing a marine natural product as a novel agonist for retinoic acid receptors with a unique bin… |
Heteromer P10276; | 100 | 1×LUF; | |||
| Crystal structure of zVDR L337H mutant-Gemini72 complex |
Heteromer Q9PTN2; | 100 | 2×H97; | |||
| Human PPARgamma ligand binding dmain complexed with SB1405 in a covalent bonded form |
Heteromer P37231; | 100 | 1×B05; | |||
| Human PPARgamma ligand binding dmain complexed with SB1451 in a covalent bonded form |
Heteromer P37231; | 100 | 1×T51; | |||
| Human PPARgamma ligand binding dmain complexed with SB1404 in a covalent bonded form |
Heteromer P37231; | 100 | 1×B4H; | |||
| Structure-activity relationship study of vitamin D analogs with oxolane group in their side chain |
Heteromer Q9PTN2; | 100 | 2×9CW; | |||
| Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear R… |
Heteromer Q9PTN2; | 100 | 2×0VO; | |||
| Structural basis for the accommodation of bis- and tris-aromatic derivatives in Vitamin D Nuclear R… |
Heteromer Q9PTN2; | 100 | 2×484; | |||
| vitamin D receptor complex with Xe4MeCF3 analog |
Heteromer Q9PTN2; | 100 | 2×XDO; | |||
| X-ray structure of human PPAR alpha ligand binding domain-lanifibranor-SRC1 coactivator peptide co-… |
Heteromer Q07869; | 100 | ||||
| VDR-ZK168281 complex |
Heteromer Q9PTN2; | 100 | 2×M9Q; | |||
| VDR complex with UG-481 |
Heteromer Q9PTN2; | 100 | 2×A1IBM; | |||
| Structure of PPARalpha-LBD/pemafibrate/SRC1 peptide |
Heteromer Q07869; | 100 | 2×P7F; | |||
| X-ray structure of human PPAR alpha ligand binding domain-elafibranor-SRC1 coactivator peptide co-c… |
Heteromer Q07869; | 100 | 1×GOL; 1×MUO; | |||
| Crystal structure of dimeric RXRalpha-LBD complexed with partial agonist CBt-PMN and SRC1 |
Heteromer P19793; | 100 | 2×9HF; 2×CA; | |||
| Crystal structure of hERa-LBD (Y537S) in complex with propylparaben |
Heteromer P03372; | 100 | 2×36M; 5×GOL; 2×EDO; 2×PEG; | |||
| Retinoic acid receptor alpha mutant - N299H |
Heteromer P10276; | 100 | 1×5Z6; | |||
| Crystal structure of hERa-LBD (Y537S) in complex with alpha-zearalenol |
Heteromer P03372; | 100 | 2×36J; 4×GOL; 2×EDO; | |||
| Crystal Structure of the wild Human ROR gamma Ligand Binding Domain. |
Heteromer G1RH57; | 100 | ||||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9NM; | |||
| Crystal structure of hERa-LBD (Y537S) in complex with butylparaben |
Heteromer P03372; | 100 | 2×27K; 2×GOL; | |||
| Crystal structure of hERa-LBD (Y537S) in complex with bisphenol-AF |
Heteromer P03372; | 100 | 2×0CZ; | |||
| Crystal structure of hERa-LBD (Y537S) in complex with benzylbutylphtalate |
Heteromer P03372; | 100 | 2×27G; 1×GOL; | |||
| Crystal structure of hERa-LBD (Y537S) in complex with benzophenone-2 |
Heteromer P03372; | 100 | 2×27M; 4×GOL; | |||
| Crystal structure of hERa-LBD (Y537S) in complex with bisphenol-A |
Heteromer P03372; | 100 | 2×2OH; | |||
| CRYSTAL STRUCTURE OF ESTROGEN RECEPTOR BETA COMPLEXED WITH WAY-697 |
Heteromer Q92731; | 100 | 2×697; | |||
| Crystal Structure of Estrogen Receptor beta complexed with WAY-338 |
Heteromer Q92731; | 100 | 2×338; | |||
| Crystal Structure of the mutant Human ROR gamma Ligand Binding Domain. |
Heteromer G1RH57; | 100 | ||||
| Vitamin D nuclear receptor complex 4 |
Heteromer Q9PTN2; | 100 | 2×DZT; | |||
| VDR complex with BXL-62 |
Heteromer Q9PTN2; | 100 | 1×U5W; | |||
| Crystal Structure of a new rexinoid bound to the RXRalpha ligand binding doamin in the RXRalpha/PPA… |
Heteromer P19793; P37231; Q92793; | 100 | 1×L79; 1×570; | |||
| Crystal Structure of Estrogen Receptor beta complexed with WAY-797 |
Heteromer Q92731; | 100 | 2×797; | |||
| Vitamin D nuclear receptor complex 3 |
Heteromer Q9PTN2; | 100 | 2×LX3; | |||
| Ligand binding to FARNESOID-X-RECEPTOR |
Heteromer Q96RI1; | 100 | 1×9LD; | |||
| Crystal structure of estrogen receptor beta complexed with 1-chloro-6-(4-hydroxy-phenyl)-naphthalen… |
Heteromer Q92731; | 100 | 2×4NA; | |||
| Vitamin D nuclear receptor complex 2 |
Heteromer Q9PTN2; | 100 | 2×E0E; | |||
| Vitamin D receptor complex 5 |
Heteromer Q9PTN2; | 100 | 2×DZW; | |||
| Human PPARgamma ligand binding domain complexed with SB1495 |
Heteromer P37231; | 100 | 1×A9C; | |||
| VDR complex with LCA derivative |
Heteromer Q9PTN2; | 100 | 2×FKC; | |||
| Human PPARgamma ligand binding dmain complexed with SB1406 in a covalent bonded form |
Heteromer P37231; | 100 | 1×6BH; | |||
| Structure of RORgt in complex with a novel agonist. |
Heteromer P51449; | 100 | 1×EDO; 1×HOJ; | |||
| Crystal structure of PPAR gamma ligand binding domain in complex with a novel partial agonist GQ-16 |
Heteromer P37231; | 100 | 1×3T0; | |||
| RORgamma (263-509) complexed with SRC2 and Compound 6 |
Heteromer P51449; | 100 | 1×4CX; | |||
| Aleglitazar, a new, potent, and balanced PPAR alpha/gamma agonist for the treatment of type II diab… |
Heteromer Q07869; | 100 | 1×RO7; | |||
| Crystal structure of RARb LBD in complex with 9cis retinoic acid |
Heteromer P10826; | 100 | 1×REA; | |||
| Design and biological evaluation of novel, balanced dual PPARa/g agonists |
Heteromer Q07869; | 100 | 1×CTM; | |||
| Novel natural PPARalpha agonist with a unique binding mode |
Heteromer Q07869; | 100 | 1×SAU; | |||
| Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with an Inhibitor 30a and GRI… |
Heteromer P03372; | 100 | 2×IAT; 2×PEG; | |||
| Estrogen Receptor Alpha Ligand Binding Domain Y537S Mutant in Complex with an Inhibitor 30o and GRI… |
Heteromer P03372; | 100 | 1×PEG; | |||
| The structure of human pregnane X receptor in complex with an SRC-1 coactivator peptide and a limon… | homo-2-mer | 100.0 | 2×G3L; | |||
| Crystal structure of the L428V mutant of pregnane X receptor ligand binding domain in complex with … | homo-2-mer | 100.0 | 2×WU6; 1×DMS; | |||
| Crystal structure of the apo form of pregnane X receptor ligand binding domain | homo-2-mer | 100.0 | ||||
| STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC CO-ACTIVATOR P… | homo-2-mer | 100.0 | 2×L7D; | |||
| Crystal structure of pregnane X receptor ligand binding domain in complex with SJPYT-310 | homo-2-mer | 100.0 | 2×WSO; 1×DMS; | |||
| Crystal structure of pregnane X receptor ligand binding domain in complex with SJPYT-328 | homo-2-mer | 100.0 | 2×WU2; | |||
| Crystal structure of pregnane X receptor ligand binding domain in complex with SJPYT-312 | homo-2-mer | 100.0 | 2×WSX; 1×DMS; | |||
| Crystal structure of the L428V mutant of pregnane X receptor ligand binding domain in apo form | homo-2-mer | 100.0 | 1×GOL; | |||
| Crystal structure of pregnane X receptor ligand binding domain in complex with SJPYT-326 | homo-2-mer | 100.0 | 1×DMS; 2×WT1; | |||
| Crystal structure of pregnane X receptor ligand binding domain in complex with SJPYT-278 | homo-2-mer | 100.0 | 2×WSX; 2×YGO; | |||
| Crystal structure of pregnane X receptor ligand binding domain in complex with SJPYT-331 | homo-2-mer | 100.0 | 2×WU6; 1×DMS; | |||
| STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC co-activator p… | homo-2-mer | 100.0 | 2×XGH; | |||
| PXR in complex with P2X4 inhibitor compound 25 | monomer | 100.0 | 1×GOL; 3×DMS; | |||
| Tethered PXR-LBD/SRC-1p apoprotein | monomer | 100.0 | ||||
| Tethered PXR-LBD/SRC-1p complexed with SR-12813 | monomer | 100.0 | 1×SRL; | |||
| STRUCTURE OF HUMAN PREGNANE X RECEPTOR LIGAND BINDING DOMAIN BOUND TETHERED WITH SRC co-activator p… | monomer | 100.0 | 1×QCG; | |||
| PXR IN COMPLEX WITH THROMBIN INHIBITOR COMPOUND 17 | monomer | 100 | 2×GOL; 1×MPD; 1×PO4; | |||
| SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTS | monomer | 100.0 | 1×Z7D; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE… | monomer | 100.0 | 1×Z7G; | |||
| SUBSTITUTED BENZYLOXYTRICYCLIC COMPOUNDS AS RETINOIC ACID-RELATED ORPHAN RECEPTOR GAMMA T AGONISTS | monomer | 100.0 | 1×TKJ; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE… | monomer | 100.0 | 1×Z7I; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE… | monomer | 100.0 | 1×Z7H; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS- RORGT(244-487)-L6-SRC1(678-692)) IN COMPL… | monomer | 100.0 | 1×O5B; 1×GOL; | |||
| Crystal structure of RAR-related orphan receptor C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) in comple… | monomer | 100.0 | 1×O5A; | |||
| CRYSTAL STRUCTURE OF RAR-RELATED ORPHAN RECEPTOR C (NHIS-RORGT(244-487)-L6-SRC1(678-692)) IN COMPLE… | monomer | 100.0 | 1×Z8I; | |||
5 SWISS-MODEL models
| Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|
| 4f3l.1.A | monomer | 0.52 | 21.47 | |||
| 5sy5.1.B | monomer | 0.52 | 21.67 | |||
| 4f3l.1.B | monomer | 0.51 | 22.57 | |||
| 8osl.1.L | monomer | 0.51 | 22.05 | |||
| 7xi3.1.A | monomer | 0.50 | 25.39 | |||
10 SWISS-MODEL models built on isoform sequence
| Isoform | Template | Oligo-state | QMEAN | Range | Ligands | Trg-Tpl Seq id (%) | |
|---|---|---|---|---|---|---|---|
| Isoform 2 | 4f3l.1.A | monomer | 0.52 | 21.47 | |||
| Isoform 2 | 5sy5.1.B | monomer | 0.52 | 21.67 | |||
| Isoform 2 | 4f3l.1.B | monomer | 0.52 | 22.57 | |||
| Isoform 2 | 8osl.1.L | monomer | 0.51 | 22.05 | |||
| Isoform 2 | 7xi3.1.A | monomer | 0.50 | 25.39 | |||
| Isoform 3 | 4f3l.1.A | monomer | 0.52 | 21.47 | |||
| Isoform 3 | 5sy5.1.B | monomer | 0.52 | 21.67 | |||
| Isoform 3 | 4f3l.1.B | monomer | 0.52 | 22.57 | |||
| Isoform 3 | 8osl.1.L | monomer | 0.51 | 22.05 | |||
| Isoform 3 | 7xi3.1.A | monomer | 0.50 | 25.39 | |||